Cytogen Inc
217330
Company Profile
Business description
Cytogen Inc is a Korea based company engaged in developing HD Microporous chip using microfluidics and nanotechnology and it captures viable CTCS (circulating tumor cells) from cancer patients blood. The firm operates in two business areas including Liquid Biopsy Applications and Liquid Biopsy Platforms.
Contact
128, Beobwon-ro
Songpa-gu
A-8 Floor, SK V1 GL Metrocity
Seoul05854
KORT: +82 269251070
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
50
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,271.23 | 24.58 | -0.05% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,497.73 | 218.10 | 1.02% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,448.26 | 32.72 | 0.51% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |